Thinking About Switching from Semaglutide to Tirzepatide?

Step 1: Understand what you're comparing (and why the difference matters here)

Semaglutide (sold as Wegovy for weight management) is a GLP-1 receptor agonist. It mimics one gut hormone involved in appetite and blood-sugar regulation. Tirzepatide, sold as Mounjaro, activates two receptors: GLP-1 and GIP. That dual action is not just a marketing distinction. In the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity who did not have diabetes. NICE's appraisal of tirzepatide (TA1026) also notes that indirect comparisons favour tirzepatide over semaglutide for weight reduction.

That does not make tirzepatide the automatic right choice for you. A higher average in a trial population tells you something about probabilities, not your personal outcome. Some people respond very well to semaglutide at full maintenance dose and have no reason to switch. Others plateau early, or find the side-effect profile of one medicine easier than the other. The comparison page on how tirzepatide and semaglutide compare across the main clinical measures sets out the trial data side by side if you want the detail.

One quick check you can do right now: look at your current dose and how long you have been on it. If you are still on a titration dose rather than the highest tolerated maintenance dose, what feels like a plateau may simply be the expected early phase of treatment. That is worth raising with your prescriber before any switch.

Step 2: Recognise the scenarios where switching is a reasonable clinical question

A switch from semaglutide to tirzepatide tends to come up in three situations. First, weight loss has stalled at the highest tolerated dose after a sustained period at maintenance, usually defined as less than five percent body weight reduction after six months, which is the review point NICE uses. Second, someone is intolerant of semaglutide in a way that might differ with a dual-agonist. Third, a person is transferring from another provider already on semaglutide and wants to explore whether tirzepatide might suit them better going forward.

If semaglutide has simply stopped producing the results it was producing, that is a different clinical question. There is a specific set of considerations around what happens when semaglutide stops working and whether tirzepatide is the right next step. The two scenarios (plateau at full dose versus loss of effect over time) have different implications.

One thing to be clear about: Ozempic is also semaglutide but it is licensed for type 2 diabetes, not weight management. If you have been using Ozempic in a weight-loss context, that is a separate issue worth discussing with a prescriber. The comparison here is specifically Wegovy (weight-management semaglutide) against Mounjaro (tirzepatide).

Step 3: Know the practical realities of the switch itself

Switching between these medicines is not simply stopping one and starting the other the same day. There are clinical considerations around washout, starting dose on tirzepatide, and how your prescriber will want to monitor the transition. The practical timing and process for switching from semaglutide to tirzepatide covers this in more detail, but the short version is: your prescriber sets the plan, not a general rule of thumb.

Tirzepatide typically starts at 2.5mg, that first pen's job is to let your system adjust, not to deliver immediate weight loss. Titration steps upward in four-week increments, guided by the prescriber. Some people find the GI side effects of tirzepatide slightly different in character from semaglutide's, though the broad profile (nausea, loose stools, reduced appetite) overlaps considerably. The NHS tirzepatide page lists the full side-effect picture clearly.

If you are currently on Wegovy and wondering whether the comparison runs in the other direction too, the considerations for switching from tirzepatide to semaglutide are genuinely different, that page addresses the specific reasons someone might move that way instead.

At a glance: how the two medicines compare on the key facts

Numbers from STEP 1 (NEJM) and SURMOUNT-1 (NEJM); SURMOUNT-5 head-to-head cited per NICE TA1026. Trial averages; individual results vary. A fuller breakdown of the benefits comparison is on the Wegovy vs Mounjaro benefits page. Which medicine suits you is a clinical decision our prescribers make with you.

When you're ready to have that conversation, start your free consultation and a prescriber at our GPhC-registered pharmacy (registration 9012878, verifiable at the GPhC register) will review your case the same day.